SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 – Results of Operations and Financial Condition.
On May 4, 2017, Synthetic Biologics, Inc., a Nevada corporation,
(the Registrant) issued the attached press release that included
financial information for the three months ended March 31, 2017.
A copy of the press release is attached as Exhibit 99.1 to this
Report on Form 8-K. The information contained in the press
release is being furnished to the Commission and shall not be
deemed incorporated by reference into any of the Registrants
registration statements or other filings with the Commission.
Item 9.01Financial Statements and Exhibits.
| (d)Exhibits. | |
| Exhibit 99.1 |
Press Release issued by Synthetic Biologics, Inc. dated May 4, 2017. |
About SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN)
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU). SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Recent Trading Information
SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) closed its last trading session down -0.008 at 0.508 with 566,919 shares trading hands.